Literature DB >> 5322321

Demonstration of tolerance to and physical dependence of N-allylnormorphine (nalorphine).

W R Martin, C W Gorodetzky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 5322321

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  10 in total

1.  Generalization of morphine and lysergic acid diethylamide (LSD) stimulus properties to narcotic analgesics.

Authors:  I D Hirschhorn; J A Rosecrans
Journal:  Psychopharmacology (Berl)       Date:  1976-05-05       Impact factor: 4.530

2.  History and development of mixed opioid agonists, partial agonists and antagonists.

Authors:  W R Martin
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Human pharmacology of narcotic antagonists.

Authors:  D R Jasinski
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 4.  The role of naltrexone in the management of drug abuse.

Authors:  H M Ginzburg; M G MacDonald
Journal:  Med Toxicol       Date:  1987 Mar-Apr

5.  Agonist and antagonist actions of morphine-like drugs on the guinea-pig isolated ileum.

Authors:  E A Gyand; H W Kosterlitz
Journal:  Br J Pharmacol Chemother       Date:  1966-09

6.  Quantitative studies on the antagonism by naloxone of some narcotic and narcotic-antagonist analgesics.

Authors:  S E Smits; A E Takemori
Journal:  Br J Pharmacol       Date:  1970-07       Impact factor: 8.739

7.  Pharmacological characterization of opiate physical dependence in the isolated ileum of the guinea-pig.

Authors:  M Luján; R Rodríguez
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

8.  Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone).

Authors:  H W Kosterlitz; A J Watt
Journal:  Br J Pharmacol Chemother       Date:  1968-06

9.  In vivo activation of a mutant mu-opioid receptor by antagonist: future direction for opiate pain treatment paradigm that lacks undesirable side effects.

Authors:  Wanling Yang; Ping-Yee Law; Xiaohong Guo; Horace H Loh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

10.  In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.

Authors:  Taline V Khroyan; Andrea Cippitelli; Nicholas Toll; John A Lawson; William Crossman; Willma E Polgar; Lawrence Toll
Journal:  Front Psychiatry       Date:  2017-04-12       Impact factor: 4.157
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.